Allurion Program increases muscle mass and decreases fat mass
- owenhaskins
- 2 days ago
- 2 min read
A presentation of a study entitled “The swallowable gastric balloon program with AI powered health coach leads to metabolically healthy weight loss in French patients,” at the Societe Francaise et Francophone de Chiurgie de l’Obesite et des Maladies Metaboliques (SOFFCOMM) meeting in Saint-Etienne, France, has assessed 1,962 patients in France treated with the Allurion Program. After four months, the average reduction in total body weight was 12.2%. Lean body mass and muscle mass as a percentage of total body weight increased, on average, by 6.0% and 6.6%, respectively. Fat mass and visceral fat index decreased, on average, by 11% and 12.2%, respectively.
“Losing weight while increasing muscle mass can enable more sustainable, long-term results for patients,” said Dr Thibaut Coste, a metabolic and bariatric surgeon in Sete, France and member of SOFFCOMM and IFSO. “These results demonstrate the Allurion Program being used at scale to achieve clinically meaningful weight loss with improvements in body composition that may correlate with improved metabolic health.”
The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, Procedureless gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan.
“We are thrilled to be back in the French market with the ability to treat patients again,” said Dr Shantanu Gaur, Founder and CEO of Allurion. “We believe that providers and patients in France will benefit from Allurion’s focus on metabolically healthy weight loss and look forward to replicating our previous successes in France in the future.”
The Allurion Gastric Balloon is an investigational device in the US.